352 related articles for article (PubMed ID: 30808625)
1. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
van Mens LJJ; de Jong HM; Fluri I; Nurmohamed MT; van de Sande MGH; Kok M; van Kuijk AWR; Baeten D
Ann Rheum Dis; 2019 May; 78(5):610-616. PubMed ID: 30808625
[TBL] [Abstract][Full Text] [Related]
2. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.
de Jong HMY; van Mens LJJ; Nurmohamed MT; Kok MR; van Kuijk AWR; Baeten DLP; van de Sande MGH
Arthritis Res Ther; 2019 Sep; 21(1):208. PubMed ID: 31521192
[TBL] [Abstract][Full Text] [Related]
3. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
Vieira-Sousa E; Alves P; Rodrigues AM; Teixeira F; Tavares-Costa J; Bernardo A; Pimenta S; Pimentel-Santos FM; Gomes JL; Aguiar R; Pinto P; Videira T; Catita C; Santos H; Borges J; Sequeira G; Ribeiro C; Teixeira L; Ávila-Ribeiro P; Martins FM; Canhão H; McInnes IB; Ribeiro RM; Fonseca JE
Ann Rheum Dis; 2020 Apr; 79(4):490-498. PubMed ID: 32193187
[TBL] [Abstract][Full Text] [Related]
4. The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes.
De Marco G; Helliwell P; McGonagle D; Emery P; Coates LC; Hensor EMA; Marzo-Ortega H
BMC Musculoskelet Disord; 2017 Jul; 18(1):303. PubMed ID: 28720139
[TBL] [Abstract][Full Text] [Related]
5. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
Weinblatt ME; Bingham CO; Mendelsohn AM; Kim L; Mack M; Lu J; Baker D; Westhovens R
Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
[TBL] [Abstract][Full Text] [Related]
6. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
Mulder MLM; Vriezekolk JE; den Broeder N; Mahler EAM; Helliwell PS; van den Hoogen FHJ; den Broeder AA; Wenink MH
Trials; 2020 Feb; 21(1):155. PubMed ID: 32041657
[TBL] [Abstract][Full Text] [Related]
7. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
[TBL] [Abstract][Full Text] [Related]
8. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
9. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
10. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
11. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
Weinblatt ME; Westhovens R; Mendelsohn AM; Kim L; Lo KH; Sheng S; Noonan L; Lu J; Xu Z; Leu J; Baker D; Bingham CO;
Ann Rheum Dis; 2014 Dec; 73(12):2152-9. PubMed ID: 24001888
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
13. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Emery P; Fleischmann RM; Doyle MK; Strusberg I; Durez P; Nash P; Amante E; Churchill M; Park W; Pons-Estel B; Xu W; Xu S; Wu Z; Hsia EC
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1732-42. PubMed ID: 23861303
[TBL] [Abstract][Full Text] [Related]
14. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study.
Mease PJ; Gladman DD; Keystone EC;
Arthritis Rheum; 2006 May; 54(5):1638-45. PubMed ID: 16646026
[TBL] [Abstract][Full Text] [Related]
15. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.
Nam JL; Villeneuve E; Hensor EM; Wakefield RJ; Conaghan PG; Green MJ; Gough A; Quinn M; Reece R; Cox SR; Buch MH; van der Heijde DM; Emery P
Ann Rheum Dis; 2014 Jun; 73(6):1027-36. PubMed ID: 24618266
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
[TBL] [Abstract][Full Text] [Related]
17. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
18. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
[TBL] [Abstract][Full Text] [Related]
20. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Mack M; Goldstein N; Braun J; Kavanaugh A
Ann Rheum Dis; 2015 Mar; 74(3):538-46. PubMed ID: 24344160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
